Center for Innovative Drug Development and Therapeutic Trials for Africa, College of Health Sciences, Addis Ababa University; KNCV TB Foundation, Challenge TB Project, Blantyre, Malawi.
Center for Innovative Drug Development and Therapeutic Trials for Africa, College of Health Sciences, Addis Ababa University, Blantyre, Malawi; Kibong'oto National Tuberculosis Hospital, Kilimanjaro, Tanzania.
Int J Mycobacteriol. 2021 Jul-Sep;10(3):255-259. doi: 10.4103/ijmy.ijmy_47_21.
Multidrug-resistant tuberculosis (MDR-TB) is one of the most urgent challenges that Malawi tends to take a firm public health action. A recent increase in multidrug MDR-TB cases, a decrease in treatment success rate, and a double increase of lost-to-follow-up call into question the country's programmatic management of MDR-TB (PMDT). As such, the study aimed at exploring programmatic challenges in managing MDR-TB in Malawi.
A comprehensive and nonsystematic search was made in PubMed and Google Scholar using mainly the keywords "MDR-TB" "extensively drug-resistant TB," Malawi. The study reviewed existing guidelines and gray literature and reviewed data obtained from the national TB program (NTP) as well.
The study found the following challenges affecting PMDT: decrease in funding, partial access to GeneXpert, delay in diagnosis, long treatment duration, lack of adequate personal protective equipment, the long turnaround time of culture results, failure to initiate all diagnosed patients on treatment, absence of alternative second-line medicines, and lack of transport from health facilities to patient homes.
If the Malawi NTP is to achieve a vision of a "TB-free Malawi," rigorous efforts at all levels must be made, including mobilizing domestic resources for improved MDR-TB program performance. Developing partners should continue providing the much-needed funding to the Malawi government to stand in the wake of the MDR-TB crisis.
耐多药结核病(MDR-TB)是马拉维急需采取坚定公共卫生行动应对的最紧迫挑战之一。近期耐多药 MDR-TB 病例增加、治疗成功率下降以及失访呼叫增加一倍,这使得该国的耐多药结核病规划管理(PMDT)受到质疑。因此,本研究旨在探讨马拉维管理耐多药结核病方面的规划挑战。
在 PubMed 和 Google Scholar 上进行了全面但非系统性的搜索,主要使用关键词“MDR-TB”“广泛耐药性结核病”和“马拉维”。本研究审查了现有指南和灰色文献,并审查了国家结核病规划(NTP)获得的数据。
研究发现了影响 PMDT 的以下挑战:资金减少、部分获得 GeneXpert、诊断延迟、治疗时间长、缺乏足够的个人防护设备、培养结果的周转时间长、未能及时为所有确诊患者开始治疗、缺乏替代二线药物以及缺乏从卫生机构到患者家中的交通工具。
如果马拉维 NTP 要实现“无结核病马拉维”的愿景,必须在各级做出艰苦努力,包括调动国内资源以提高 MDR-TB 项目的绩效。发展伙伴应继续向马拉维政府提供急需的资金,以应对耐多药结核病危机。